Inhibitors of catecholamine metabolizing enzymes cause changes in S-adenosylmethionine and S-adenosylhomocysteine in the rat brain

Neurochemistry International

Volumn 32, Issue 1, 1998, Pages 53-59

  Yassin, M S ^a   Cheng, H ^a   Ekblom, J ^a   Oreland, L ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; METHIONINE ADENOSYLTRANSFERASE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; TOLCAPONE;

ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN HOMOGENATE; CONTROLLED STUDY; DOPAMINE METABOLISM; ENZYME ACTIVITY; MALE; METHYLATION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT;

ANIMALS; BENZOPHENONES; BRAIN; CATECHOL O-METHYLTRANSFERASE; ENZYME INHIBITORS; KINETICS; MALE; METHIONINE ADENOSYLTRANSFERASE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NITROPHENOLS; PHENELZINE; RATS; RATS, SPRAGUE-DAWLEY; S-ADENOSYLHOMOCYSTEINE; S-ADENOSYLMETHIONINE;

ANIMALIA;

EID: 0031976109     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(97)00047-8     Document Type: Article

References (35)

1. Barbeau, A. (1986). Parkinson's disease: clinical features and etiopatholology, in Handbook of Clinical Neurology, eds P.J. Vinken, G.W. Bruyn and H.L. Klawans, Vol. 5, pp. 87-152. Elsevier, Amsterdam.
2. Benson, R., Crowell, B., Hill, B., Doonquah, K., & Charlton, C. (1993). The effects of L-dopa on the activity of methionine adenosyltransferase: relevance to L-dopa therapy and tolerance. Neurochem. Res., 18, 325-330.
3. Butcher, S. P., Fairbrother, I. S., Kelly, J. S. and Arbuthnott, G. W. (1990). Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J. Neurochem., 55, 981-988.
4. Bloem, B. R., Irwin, I., Buruma, O. J., Haan, J., Roos, R. A., Tetrud, J. W., & Langston, J. W. (1990). The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J. Neurol. Sci., 97, 273-293.
5. Bottiglieri, T., Hyland, K., & Reynolds, E. H. (1994). The clinical potential of ademetionine (S-adenosyimethionine) in neurological disorders. Drugs, 48, 137-152.
6. Charlton, C. G., & Crowell, B., Jr. (1992). Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Pharmacol. Biochem. and Behav., 43, 423-431.
7. Charlton, C. G., & Crowell, B., Jr. (1995). Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S-adenosylmethionine. Mol. Chem. Neuropathol., 26, 269-284.
8. Charlton, C. G., & Mack, J. (1994). Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism. Mol. Neurobiol., 9, 149-161.
9. Chiang, K. P., Gordon, K. R., Tal, J., Zeng, C. G., Doctor, P. B., Pardhasaradhi, K., & McCann, P. P. (1996). S-adensylmethionine and methylation. FASEB J., 10, 471-480.
10. Chouza, C., Aljanati, R., Scaramelli, A., De Medina, O., Caamano, J. L., Buzo, R., Fernandez, A., & Romero, S. (1989). Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients. Acta Neurol. Scand., 126, 127-137.
11. Dingemanse, J., Jorga, K., Zurcher, G., Schmitt, M., Sedek, G., Da Prada, M., & Brummelen, P. V. (1995). Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tocalpone and single-dose levodopa. Br. J. Clin. Pharmacol., 40, 253-262.
12. Duvoisin, R. C. (1982). The cause of Parkinson's disease, in Neurology, eds C.D. Mardsden and S. Fahn, Vol. 2, pp. 8-24. Butterworth Scientific, London.
13. Eloranta, T. O. (1977). Tissue distribution of S-adenosylmethionine and S-adenosylhomocysteine in the rat: effect of age, sex and methionine administration on the metabolism of S-adenosylmethionine S-adenosylhomocysteine and polyamines. Biochem. J., 166, 521-529.
14. Garib, A., Sada, N., Chabannes, B., Cronenberger, L., & Pacheco, H. (1982). The regional concentrations of S-adenosyl-L-mehonine, S-adenosylhomocysteine, and adenosine in rat brain. J. Neurochem., 38(3), 810-815.
15. Gerlach, M., Youdim, M. B. H., & Riederer, P. (1994). Is selegiline neuroprotective in Parkinson's disease? J. Neural Transm. [Suppl], 41, 177-188.
16. Goldstein, M., & Lieberman, A. (1992). The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease. Neurology, 4(42), 8-12.
17. Gomes, T. C., Jonas, E., & Oreland, L. (1997). Regulation of methionine adenosyltranferase activity in SH-SY5Y human neuroblastoma cells. Biochem. Pharmacol., in press.
18. Gomes, T. C., Löfberg, C., Trolin, G., & Oreland, L. (1994). Brain ATP: L-methionine S-adenosyltransferase (MAT), S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH): regional distribution and age-related changes. Europ. Neuropsychopharmacol., 4, 469-477.
19. Hallman, J., Oreland, L., Edman, G., & Schalling, D. (1987). Thrombocyte monoamine oxidase activity and personality traits in women with severe premenstrual syndrome. Acta Psychiatr. Scand., 76, 225-234.
20. Hargrave, R., & Ashford, J. W. (1992). Phenelzine treatment of depression in Parkinson's disease [letter]. Am. J. Psychiatry, 149, 1751-1752.
21. Hoffman, D. R., Cornatzer, W. E., & Duerre, J. A. (1979). Relationship between tissue levels of S-adenosylmethionine, S-adenosylhomocysteine and transmethylation reactions. Can. J. Biochem., 57, 56-65.
22. Jellinger, K. (1989). Pathology of Parkinson's syndrome, in Handbook of Experimental Pharmacology, ed. D.B. Calne, Vol. 88, pp. 47-112. Spinger, Berlin.
23. Jellinger, K. (1991). Pathology of Parkinson's disease: changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol., 14, 153-197.
24. Lange, K. W., Youdim, M. B. H., & Riederer, P. (1992). Neurotoxicity in Parkinson's disease. J. Neural Transm. [Suppl], 38, 27-44.
25. Langston, J. W. (1988) The etiology of Parkinson's disease: new directions for research, in Parkinson's Disease and Movement Disorders, eds J. Jankovic and E. Tolosa, pp. 75-85. Urban and Schwarzenberg, Baltimore-Munich.
26. Markwell, M. A. K., Haas, S. M., Bieber, L. L., & Tolbert, N. E. (1978). A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem., 87, 206-210.
27. McKenna, K. F., Baker, G. B., Coutts, R. T., & Greenshaw, A. J. (1992). Chronic administration of the antidepressant-antipanic drug phenelzine and its N-acetylated analogue: effects on monoamine oxidase, biogenic amines, and alpha 2-adrenoreceptor function. J. Pharm. Sci., 81, 832-835.
28. Mudd, S. H., & Cantoni, G. L. (1964). Biological transmethylation methyl-group neogenesis and other one carbon metabolic reactions dependant upon tetrahydofolic acid, in Comprehensive Biochemistry, eds M. Florkin and E.H. Stotz, Vol. 15, pp. 1-47. Elsevier, Amesterdam.
29. Myllylä, V. V., Sotaniemi, K. A., Tuominen, J., & Heinonen, E. H. (1989). Selegiline as primary treatment in early phase Parkinson's disease an interim report. Acta Neurol. Scand., 126, 177-182.
30. Oden, K. L., & Clarke, S. (1983). S-adenosylmethionine synthetase from human erythrocytes: role in the regulation of cellular S-adenosylmethionine levels. Biochem., 22, 1978-1986.
31. Olney, G. W. (1989). Excitatory amino acids and neuropsychiatric disorders. Biol. Psychiatry, 26, 505-526.
32. Oreland, L. (1991). Monoamine oxidase, dopamine and Parkinson's disease. Acta Neurol. Scand. [Suppl], 84(136), 60-65.
33. Schatz, R. A., Vunnam, C. R., & Sellinger, O. Z. (1977). S-adenosyl-L-homocysteine in brain. Regional concentrations, catabolism and the effects of methionine sulfoximine. Neurochem. Res., 2, 27-38.
34. Wurtman, R. J., Rose, C. M., Matthysse, S., Stephenson, J., & Baldessarini, R. (1970). L-Dihydroxyphenylalanine: effect on S-adenosylmethionine in brain. Science, 169, 395-397.
35. Yu, P. H., Davis, B. A. and Durden, D. A. (1991). Enzymatic N-methylation of phenelzine catalyzed by phenylethanolamine N-methyltransferase. Prog. Neuro-psychopharmacol. Biol. Psychiat., 75, 307-312.